GLORIA is an international investigator – initiated trial aiming to prove (or disprove) that the addition of chronic low dose glucocorticoids to current anti-rheumatic therapy is cost-effective and safe, in elderly patients with Rheumatoid Arthritis (RA). About 50% of patients are currently treated with this strategy.
GLORIA is funded by the EU Horizon 2020 Program. >>
In the Netherlands, there have been several publicity actions to expose GLORIA to patients as well as others that could be interested in the trial. An interesting movie with an interview to Professor Martin Boers was produced and it is already available on the website of the Dutch Arthritis Association (Reumafonds).
The subtitle of the movie will also be translated in all participating language Read more
This meeting will take place at EULAR (Madrid) on 16th June 2017. An update on trial status is expected and the recruitment efforts will be discussed.
This will be an excellent moment to share the experiences about GLORIA trial which have already recruited patients in seven different countries: Netherlands, Germany, Portugal, Slovakia, Italy, Hungary and Romania.
A presentation of the survey Read more
One of our newst additions to the already fairly extense GLORIAs Document Center is an interesting one:
Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort.
Please click to find an overview of the article, together with a pubmed link!
The next EULAR Annual European Congress of Rheumatology will take place from 14 - 17 June 2017 in Madrid, Spain.
The annual EULAR Congress continues to be a major event for the exchange of scientific and clinical information. It will be a platform to facilitate interactions between patients, medical doctors, scientists, health professionals, and professionals representing the pharmaceutical ind Read more